JP Morgan Chase
PRVL

JP Morgan Chase’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

JP Morgan Chase’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,560
Closed -$175K – 6562
2020
Q4 		$175K Sell
7,560
-39,047
-84% -$495K ﹤0.01% 4855
2020
Q3 		$463K Buy
46,607
+7,354
+19% +$98.7K ﹤0.01% 4020
2020
Q2 		$585K Buy
39,253
+7,258
+23% +$112K ﹤0.01% 3789
2020
Q1 		$389K Buy
31,995
+17,856
+126% +$284K ﹤0.01% 3948
2019
Q4 		$223K Buy
14,139
+11,707
+481% +$149K ﹤0.01% 4622
2019
Q3 		$30K Buy
+2,432
New +$27.6K ﹤0.01% 5324

JP Morgan Chase's PRVL Position: Q1 2021 in Review

JP Morgan Chase sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 7,560 shares — an estimated $175K sold.

JP Morgan Chase first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $585K in Q2 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • JP Morgan Chase reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • JP Morgan Chase sold 7,560 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $175K.
  • JP Morgan Chase first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
  • JP Morgan Chase's Prevail Therapeutics Inc. Common Stock position peaked at $585K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on JP Morgan Chase's 13F filing for Q1 2021, filed 12 May 2021.